Biovitrum AB to acquire Kepivance and Stemgen and exclusively licence Kineret from Amgen (AMGN); upfront payment $130 M.

Biovitrum AB (publ) and Amgen have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance (palifermin) and Stemgen (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive licence to Kineret (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value. The financial terms of the transaction include an upfront payment of about $130 M, consisting of $110 M in cash and ordinary shares of Biovitrum, representing a value of $20 M at the time of closing, subject to certain adjustments provided in the acquisition …